We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+8.96%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$5.08B
AUM Growth
+$407M
Cap. Flow
+$226M
Cap. Flow %
4.45%
Top 10 Hldgs %
23.59%
Holding
154
New
18
Increased
54
Reduced
21
Closed
16

Top Buys

Rank Stock Value
1
DOCS icon
Doximity
DOCS
+$69.6M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$63M
3
MDB icon
MongoDB
MDB
+$59.3M
4
DV icon
DoubleVerify
DV
+$47.6M
5
FLYW icon
Flywire
FLYW
+$39.8M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$165M
2
DUOL icon
Duolingo
DUOL
+$33.1M
3
KURA icon
Kura Oncology
KURA
+$32.8M
4
COGT icon
Cogent Biosciences
COGT
+$30.6M
5
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$25.8M

Sector Composition

Rank Sector Weight
1 Healthcare 38.81%
2 Technology 24%
3 Industrials 15.64%
4 Consumer Discretionary 5.21%
5 Utilities 4.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CWEN icon
51
Clearway Energy Class C
CWEN
$4.94B
$36.4M 0.72%
1,141,486
+299,086
+36% +$11M
ZYME icon
52
Zymeworks
ZYME
$1.67B
$33.1M 0.65%
5,380,200
– –
LSCC icon
53
Lattice Semiconductor
LSCC
$17.7B
$31.4M 0.62%
638,544
-12,000
-2% -$664K
IMVT icon
54
Immunovant
IMVT
$8.11B
$30M 0.59%
5,372,512
– –
BPMC
55
DELISTED
Blueprint Medicines
BPMC
$28.9M 0.57%
438,500
– –
ASML icon
56
ASML
ASML
$634B
$28.7M 0.56%
69,086
+86
+0.1% +$43.1K
COUR icon
57
Coursera
COUR
$1.51B
$28.6M 0.56%
2,654,716
+15,623
+0.6% +$207K
TSM icon
58
TSMC
TSM
$2.09T
$28.2M 0.56%
411,827
+1,827
+0.4% +$151K
MASS icon
59
908 Devices
MASS
$313M
$28.2M 0.56%
1,715,801
+217,700
+15% +$4.23M
NVT icon
60
nVent Electric
NVT
$23.4B
$27.6M 0.54%
873,300
+14,100
+2% +$471K
VRSK icon
61
Verisk Analytics
VRSK
$26.1B
$26.9M 0.53%
157,800
– –
MIRM icon
62
Mirum Pharmaceuticals
MIRM
$6.87B
$26.8M 0.53%
+1,275,000
New +$30.7M
BEPC icon
63
Brookfield Renewable
BEPC
$6.04B
$25.3M 0.5%
775,019
– –
NBIX icon
64
Neurocrine Biosciences
NBIX
$18.7B
$25M 0.49%
235,000
– –
NDAQ icon
65
Nasdaq
NDAQ
$53.2B
$24.8M 0.49%
437,225
+77,525
+22% +$4.56M
HASI icon
66
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$4.85B
$24.6M 0.48%
822,664
– –
REXR icon
67
Rexford Industrial Realty
REXR
$8.56B
$23.9M 0.47%
460,209
-41,084
-8% -$2.54M
APLS
68
DELISTED
Apellis Pharmaceuticals
APLS
$23.2M 0.46%
+339,355
New +$20.1M
STE icon
69
Steris
STE
$22.5B
$23.2M 0.46%
139,352
+27,167
+24% +$5.53M
XENE icon
70
Xenon Pharmaceuticals
XENE
$6.2B
$23.1M 0.46%
641,200
+171,500
+37% +$6.17M
ANNX icon
71
Annexon
ANNX
$863M
$22.4M 0.44%
3,626,508
– –
CDW icon
72
CDW
CDW
$18.6B
$22.3M 0.44%
142,700
+60,100
+73% +$10.3M
RGEN icon
73
Repligen
RGEN
$8.1B
$22.3M 0.44%
119,000
– –
WMB icon
74
Williams Companies
WMB
$86.7B
$21.6M 0.42%
752,900
+35,200
+5% +$1.15M
BCYC
75
Bicycle Therapeutics
BCYC
$280M
$19.9M 0.39%
853,800
– –
1 2
3
4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q3 2022 Portfolio in Review

As of Q3 2022, Eventide Asset Management held 154 positions worth $5.08B, up 8.7% from $4.68B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Eventide Asset Management deployed $226M of net new capital in Q3 2022, opening 18 new positions and adding to 54 existing holdings. Its largest new stake was DoubleVerify: 1,847,144 shares worth $50.5M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, up from 35% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Cogent Biosciences, an estimated $30.6M trimmed.

  • Eventide Asset Management's largest Q3 2022 buy was DoubleVerify: 1,847,144 shares worth $50.5M.
  • Eventide Asset Management added most to Doximity in Q3 2022, an estimated $69.6M increase.
  • Eventide Asset Management's biggest Q3 2022 reduction was Cogent Biosciences, cutting an estimated $30.6M.
  • Eventide Asset Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q3 2022, selling an estimated $165M.
  • Eventide Asset Management's ten largest holdings make up 24% of its $5.08B portfolio in Q3 2022.
  • Eventide Asset Management opened 18 new positions and closed 16 in Q3 2022.
  • Eventide Asset Management's portfolio value rose 8.7% quarter-over-quarter to $5.08B.

Based on Eventide Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.